Innate Pharma appoints Professor Jean-Yves Blay to supervisory board.
M2 EQUITYBITES-January 31, 2018-Innate Pharma appoints Professor Jean-Yves Blay to supervisory board
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Innate Pharma SA (EPA: IPH) has appointed Professor Jean-Yves Blay to its supervisory board, the company announced on Wednesday.
Professor Blay will bring a wealth of experience to the board, having held the post of general director of the Centre LA@on BA@rard in Lyon, France, since 2014 and secretary of the Oncology Commission of the French Academy of Medicine since 2016.
Prior to these positions, he was president of the European Organisation for Research and Treatment of Cancer (EORTC) between 2009 and 2012.
He currently holds numerous other university and hospital positions and is a member of the European Union Committee of Experts of Rare Diseases, and the European Commission's Scientific Panel for Health (SPH).
Between 2012 and 2016, Professor Blay served as faculty coordinator for Sarcoma for the European Society of Medical Oncology. He is also a member of numerous scientific societies and academic expert groups, has received several honours, and is the author of over 200 publications in the last three years.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jan 31, 2018|
|Previous Article:||HiQ International posts profit of SEK165.3m in 2017.|
|Next Article:||EMA review for sleeping sickness treatment sought by Sanofi and DNDi.|